Co-Diagnostics 과거 순이익 실적
과거 기준 점검 0/6
Co-Diagnostics 의 수입은 연평균 -56.6%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 15.3%의 비율로 증가했습니다. 매출은 연평균 68.2%의 비율로 감소해 왔습니다.
핵심 정보
-56.64%
순이익 성장률
-55.05%
주당순이익(EPS) 성장률
| Medical Equipment 산업 성장률 | 8.90% |
| 매출 성장률 | -68.23% |
| 자기자본이익률 | -302.34% |
| 순이익률 | -6,753.69% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Oct 18
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Narrative Update on Co-Diagnostics Analysts have marginally increased their price target for Co-Diagnostics from $3.00 to $3.00, citing minimal changes in valuation inputs and updated financial forecasts as the rationale for this slight adjustment. What's in the News Announced development of a proprietary sample preparation instrument to streamline its point-of-care Co-Dx PCR Mycobacterium Tuberculosis Test.내러티브 업데이트 • Oct 04
Regulatory Approvals And Launches Will Expand Decentralized Healthcare Access
Analysts have significantly lowered their price target for Co-Diagnostics from $10.00 to $3.00, citing revised fair value estimates and a reduced expectation for future earnings multiples. What's in the News Co-Diagnostics completed a $3.85 million Follow-on Equity Offering, issuing 9,619,000 shares of common stock at $0.40 per share in a registered direct offering.
새로운 내러티브 • May 04
Co-Dx PCR Platform And FDA 510(K) Clearance Will Expand Market Reach
Advancements in PCR platform and manufacturing enhance commercialization, potentially increasing revenues and profit margins through scale efficiencies.분석 기사 • Feb 25
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...분석 기사 • Jun 14
Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • May 18
One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%
One thing we could say about the covering analyst on Co-Diagnostics, Inc. ( NASDAQ:CODX ) - they aren't optimistic...분석 기사 • Apr 14
A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)
Key Insights Co-Diagnostics' estimated fair value is US$1.40 based on 2 Stage Free Cash Flow to Equity Current share...Seeking Alpha • Sep 07
Co-Diagnostics: Hold Thesis Remains Well Intact
Summary We reiterate the hold thesis on Co-Diagnostics following Q2 FY22 earnings. Covid-19 turnover continues to diminish for CODX whilst surging for rival test providers. Inventory levels for the company spiked year over year as the Omicron-led demand in testing faded. We've valued CODX at $3.24 suggesting shares are adequately priced by the market consensus. From the Portfolio Manager's Desk Having witnessed the rapid cooling of Omicron-led demand in Covid-19 diagnostics, the Sars-CoV-2 assay market is looking increasingly unattractive. Here revisit Co-Diagnostics, Inc. (CODX) a name that we are extremely familiar with having tracked the company across the entire span of the pandemic. We were buyers of the stock in January FY21 as a speculative position built around our core holdings in med-tech. We've since exited the position with a small loss, and believe impeding macro-headwinds remain for the company. With Covid-assay demand still diminishing, supplier inventory levels are likely at historically low levels, and the question is if they will seek to restore/repurchase inventory levels back to FY21 highs. The bulk of CODX's turnover is derived from Covid-19, so this is key to the investment debate for CODX looking ahead. Investment Thesis Summary Here we reiterate a hold rating on CODX with a $3.24 price target. With Covid-19 test revenue diminishing substantially in Q2 FY22 [whilst rival test makers revenue surged YoY] there is low predictability of the company's future cash flows by estimation. Valuations are supportive of a neutral view and forward looking earnings are marred by the fact Covid-19 test volumes will likely dwindle as time goes on. Although it has other innovations in the pipeline, the timing and timeline for these are fluid for now and there's no concrete launch dates. We need further clarity on how CODX intends to distribute its top-line ex-Covid. Rate hold price target $3.24. Co-Diagnostics' Q2 earnings illustrate headwinds CODX came in with a fairly weak set of numbers when compared to Q2 FY21. It clipped revenue of just $5 million ("mm"), an 81.6% YoY decrease from $27.4mm the year prior. The substantial tightening at the top line came as demand for CODX's Logix Smart Covid-19 test, that was developed in response to the pandemic [more on this later]. CODX also recognized a 54% YoY decline in sales to third parties of ~$75,000. Quarterly gross profit margin narrowed by 9 percentage points to 81.8% following the tighter revenue and unit volumes whilst fixed production costs made up a larger portion of revenues. Moving down the P&L, OPEX also narrowed by ~36% YoY to $8.3mm secondary to lower variable expenditures tied to sales volume. Quarterly operating loss came in at $4.17mm down from a profit of ~$11.8mm the year prior, again from the lower revenues and a $353,000 YoY gain in depreciation and amortization expense. Meanwhile R&D investment for the quarter came in 16.7% lower to $3.9mm from a relatively high base in Q2 FY21, and the company also bought back $2.6mm of its own stock. It brought this down to a quarterly net loss of ~$2.7mm or -$0.08/share, down from a $9.7mm/ $0.34 per share after-tax profit last year. CODX did still see profitability from CFFO during the quarter. In fact, for the 6-months to Q2 FY22, it printed $9.4mm [$0.28/share] in cash from operations. However, also noted is that it added $2.9mm stock based compensation expense to this, whereas accounts receivable value jumped $8.56mm during this time. Free cash flow ("FCF") has narrowed on a sequential basis for the company and came in at $1.15mm for the quarter and $25.2mm for the TTM. However, one point to note is that its TTM return on invested capital ("ROIC") has remained in the double digits at 24.2% last quarter and comfortably covers CODX's WACC hurdle of ~6.2% by ~4 turns. As seen in Exhibit 1, ROIC has remained consistently high whilst FCF is reinvested heavily back into the business. Exhibit 1. Quarterly FCF continues to decline whilst TTM ROIC remains buoyant, albeit tightening as well. This adds a bullish tilt to the risk/reward calculus and provides a solid bedrock for the company to continue seeing return on its investments looking ahead. Data: HB Insights, CODX SEC Filings Outlook weakened on lower test demand As have previously outlined, Covid-19 provided CODX with stellar revenue and earnings leverage that was reflected in its numbers at the time. Previously, we advocated that CODX's test volumes should remain high as there was currently no test to distinguish between influenza and Covid-19, a tailwind for assay kit producers. Management remain equally as optimistic, per language from CEO Dwight Egan on the Q2 earnings call: This dramatic shift [decrease] in testing behavior was widely felt across the diagnostics industry. Experts believe other waves of COVID variants are all, but inevitable. However, the timing and severity are impossible to predict with every new variant, including the possibility of immune escape as variants and sub-variants by for dominance. In the U.S. alone, we are still seeing around a 100,000 new COVID cases reported per day, over 6,000 COVID-related hospital admissions and nearly 400 deaths, all evidence to date points to a resilient mutable virus with no indication it will go away and that we will be living with it for years to come." Clearly, however, the Omicron-led demand for assay volumes has subsided and this is reflected in inventory values of both manufacturers and suppliers of the tests. We see evidence of this in CODX's numbers as its inventory value increased ~135% YoY in the second quarter to $4.7mm.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Co-Diagnostics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 1 | -49 | 11 | 20 |
| 31 Dec 25 | 1 | -47 | 11 | 19 |
| 30 Sep 25 | 1 | -32 | 16 | 19 |
| 30 Jun 25 | 1 | -36 | 19 | 19 |
| 31 Mar 25 | 3 | -36 | 20 | 20 |
| 31 Dec 24 | 4 | -38 | 21 | 21 |
| 30 Sep 24 | 7 | -41 | 20 | 22 |
| 30 Jun 24 | 9 | -38 | 20 | 23 |
| 31 Mar 24 | 7 | -39 | 21 | 24 |
| 31 Dec 23 | 7 | -35 | 21 | 23 |
| 30 Sep 23 | 5 | -43 | 22 | 22 |
| 30 Jun 23 | 7 | -38 | 22 | 21 |
| 31 Mar 23 | 12 | -32 | 21 | 19 |
| 31 Dec 22 | 34 | -14 | 22 | 17 |
| 30 Sep 22 | 53 | 15 | 20 | 15 |
| 30 Jun 22 | 78 | 28 | 22 | 16 |
| 31 Mar 22 | 101 | 40 | 26 | 17 |
| 31 Dec 21 | 98 | 37 | 25 | 15 |
| 30 Sep 21 | 105 | 42 | 25 | 14 |
| 30 Jun 21 | 96 | 46 | 21 | 9 |
| 31 Mar 21 | 93 | 51 | 15 | 5 |
| 31 Dec 20 | 75 | 42 | 13 | 3 |
| 30 Sep 20 | 48 | 28 | 9 | 2 |
| 30 Jun 20 | 26 | 10 | 7 | 2 |
| 31 Mar 20 | 2 | -6 | 5 | 1 |
| 31 Dec 19 | 0 | -6 | 5 | 1 |
| 30 Sep 19 | 0 | -6 | 5 | 1 |
| 30 Jun 19 | 0 | -6 | 5 | 1 |
| 31 Mar 19 | 0 | -6 | 5 | 1 |
| 31 Dec 18 | 0 | -6 | 5 | 1 |
| 30 Sep 18 | 0 | -6 | 5 | 1 |
| 30 Jun 18 | 0 | -8 | 5 | 1 |
| 31 Mar 18 | 0 | -8 | 4 | 1 |
| 31 Dec 17 | 0 | -7 | 4 | 1 |
| 30 Sep 17 | 0 | -6 | 3 | 1 |
| 30 Jun 17 | 0 | -3 | 1 | 1 |
| 31 Mar 17 | 0 | -2 | 1 | 1 |
| 31 Dec 16 | 0 | -2 | 1 | 1 |
| 30 Sep 16 | 0 | -2 | 1 | 1 |
| 31 Dec 15 | 0 | -2 | 1 | 1 |
양질의 수익: CODX 은(는) 현재 수익성이 없습니다.
이익 마진 증가: CODX는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: CODX은 수익성이 없으며 지난 5년 동안 손실이 연평균 56.6% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 CODX의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: CODX은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: CODX는 현재 수익성이 없으므로 자본 수익률이 음수(-302.34%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/11 16:14 |
| 종가 | 2026/06/11 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Co-Diagnostics, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jason McCarthy | Maxim Group |
| James Sidoti | Sidoti & Company, LLC |